FEMY — FEMASYS INC

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1339005 ·
Last close
$1.12
Market Cap
$9.38M
52W High
$20.80
52W Low
$1.07
ADV30
101,465
Next earnings
—
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 404,597 217,101 -4,450,010 -4,564,815 35,087,658 23,913,946 8,059,496
Jun 2026 331,827 189,391 -5,065,874 -4,469,095 12,289,582 1,443,502 8,258,635
Mar 2026 424,889 266,283 -4,223,533 846,100 16,495,245 5,386,041 9,205,352
Dec 2025 813,387 510,262 -4,622,728 -3,950,305 20,724,177 9,266,353 14,854,875

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,651,812
Investing CF
$-537,848
Financing CF
$16,415,095
CapEx
$-537,848
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.53
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-149,449,139
Inventory
$6,191,277
Receivables
$151,049
ST Investments
—
EBIT TTM
$-10,458,944
Pretax Income TTM
$-11,761,771
Interest Exp TTM
$1,302,827
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,299,497
EBITDA
$-17,229,926
Free Cash Flow
$-11,230,021
Enterprise Value
$15,239,281
Total Cash
$1,443,502
Total Debt
$4,790,245
Shares Out
8,375,027
Trailing EPS
$-3.28
Book Value
$1.97
ROE
-425.0%
ROA
-84.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,293,313 -17,588,669 -18,627,887 20,724,177 14,854,875 5,869,302 -18,690,565
Dec 2024 1,629,108 -17,785,805 -18,816,628 12,445,002 10,140,580 2,304,422 -19,444,009
Dec 2023 1,071,970 -14,508,415 -14,247,124 27,755,825 9,403,236 18,352,589 -11,280,546
Dec 2022 1,206,218 -11,600,264 -11,394,170 16,895,570 1,653,051 15,242,519 -10,731,973

TTM Snapshot

Revenues TTM
$2,299,497
NetIncome TTM
$-11,768,121
OpCashFlow TTM
—
Assets (Latest)
$12,289,582
Forward EPS
$-2.12

Peers — same industry

TickerNameMarket CapLastDaily %
SINT Sintx Technologies, Inc. $9.22M $1.22 —
LFWD Lifeward Ltd. $8.80M $3.10 —
PLSM Pulsenmore Ltd. $8.78M $1.35 —
RGNT REGENTIS BIOMATERIALS LTD. $8.57M $1.22 —
ALRTF ALR Technologies SG Ltd. $10.46M $0.02 —

News headlines (Yahoo Finance, 1h cache)

Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
2026-11-13 21:05 · Yahoo
Femasys Appoints John Moorhead to Board of Directors
2026-10-30 13:00 · Yahoo
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
2026-10-20 13:00 · Yahoo
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
2026-10-14 13:00 · Yahoo
Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands
2026-10-08 14:38 · Yahoo
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
2026-10-08 13:00 · Yahoo
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
2026-09-15 13:00 · Yahoo
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
2026-08-26 13:00 · Yahoo
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
2026-08-19 17:36 · Yahoo
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
2026-08-19 16:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.